HOTH
- Hoth Therapeutics, Inc.
()
Overview
Company Summary
Hoth Therapeutics, Inc. (HOTH) is a clinical-stage biopharmaceutical company primarily focused on the development of innovative therapies for various dermatological conditions and autoimmune disorders. The company's mission is to leverage breakthrough science and novel technologies to improve patient outcomes and address unmet medical needs.
HOTH utilizes a multi-pronged approach to advance its portfolio of therapeutic candidates. The company seeks to harness the power of targeted therapies, immunotherapies, and gene therapy to develop potential treatments for conditions such as eczema, psoriasis, chronic wounds, diabetic ulcers, and cancer.
One of Hoth Therapeutics' leading therapeutic candidates is BioLexa, a proprietary topical product that aims to treat atopic dermatitis (eczema) and reduce the severity and frequency of outbreaks. BioLexa is designed to use an antimicrobial peptide, supplemented with other ingredients, to combat the microbial component of the disease and promote skin healing.
Additionally, Hoth Therapeutics collaborates with renowned research institutions, such as the George Washington University, to explore and develop novel approaches to tackle dermatological and autoimmune disorders. The company actively seeks partnerships and licensing opportunities for its technologies and therapeutic candidates to accelerate their development and commercialization.
Overall, the core focus of Hoth Therapeutics, Inc. is to advance innovative therapies and make a significant impact on patients suffering from dermatological conditions and autoimmune disorders, ultimately improving their quality of life.